Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $135.08 Average Price Target from Analysts

Abivax SA Sponsored ADR (NASDAQ:ABVX) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $135.0833.

ABVX has been the topic of several research reports. Barclays started coverage on shares of Abivax in a report on Monday, October 13th. They set an “overweight” rating and a $142.00 price target on the stock. Truist Financial set a $140.00 target price on shares of Abivax in a research note on Monday, November 24th. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Guggenheim reissued a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. Finally, Wolfe Research raised Abivax to a “strong-buy” rating in a report on Thursday, November 6th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp acquired a new position in shares of Abivax during the third quarter worth $36,000. Bank of America Corp DE grew its stake in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. acquired a new stake in Abivax in the third quarter valued at $52,000. Finally, Cubist Systematic Strategies LLC raised its position in Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after purchasing an additional 2,595 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

Abivax Price Performance

Abivax stock opened at $118.84 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. Abivax has a 52 week low of $4.77 and a 52 week high of $148.83. The stock has a market capitalization of $9.32 billion, a P/E ratio of -28.43 and a beta of 0.68. The stock has a fifty day moving average of $122.39 and a 200-day moving average of $91.13.

Abivax (NASDAQ:ABVX) last released its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The business had revenue of ($4.92) million during the quarter. On average, sell-side analysts expect that Abivax will post -2.83 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.